US5994103A
(en)
|
1995-06-02 |
1999-11-30 |
Human Genome Science, Inc. |
Human stanniocalcin-alpha
|
FR2751989B1
(fr)
*
|
1996-08-01 |
1998-10-30 |
Soc D Rech Et De Dev En Activa |
Methode d'identification de cellules eucaryotes par fixation desdites cellules sur un support et support pour mettre en oeuvre ladite methode
|
US6544797B1
(en)
*
|
1997-04-09 |
2003-04-08 |
Biosite Diagnostics, Inc. |
Compositions and methods for inhibiting light-induced inactivation of biological reagents
|
US6830731B1
(en)
*
|
1998-01-05 |
2004-12-14 |
Biosite, Inc. |
Immunoassay fluorometer
|
US6392894B1
(en)
|
1998-01-05 |
2002-05-21 |
Biosite Incorporated |
Media carrier for an assay device
|
US6096726A
(en)
*
|
1998-03-11 |
2000-08-01 |
Surface Solutions Laboratories Incorporated |
Multicomponent complex for use with substrate
|
ES2390425T3
(es)
|
2000-12-22 |
2012-11-12 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Uso de moléculas de orientación repulsivas (RGM) y sus moduladores
|
US20040203083A1
(en)
*
|
2001-04-13 |
2004-10-14 |
Biosite, Inc. |
Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases
|
US20040253637A1
(en)
*
|
2001-04-13 |
2004-12-16 |
Biosite Incorporated |
Markers for differential diagnosis and methods of use thereof
|
US7713705B2
(en)
*
|
2002-12-24 |
2010-05-11 |
Biosite, Inc. |
Markers for differential diagnosis and methods of use thereof
|
US7524635B2
(en)
*
|
2003-04-17 |
2009-04-28 |
Biosite Incorporated |
Methods and compositions for measuring natriuretic peptides and uses thereof
|
US20030219734A1
(en)
*
|
2001-04-13 |
2003-11-27 |
Biosite Incorporated |
Polypeptides related to natriuretic peptides and methods of their identification and use
|
US20040121350A1
(en)
*
|
2002-12-24 |
2004-06-24 |
Biosite Incorporated |
System and method for identifying a panel of indicators
|
US20030199000A1
(en)
*
|
2001-08-20 |
2003-10-23 |
Valkirs Gunars E. |
Diagnostic markers of stroke and cerebral injury and methods of use thereof
|
US20040126767A1
(en)
*
|
2002-12-27 |
2004-07-01 |
Biosite Incorporated |
Method and system for disease detection using marker combinations
|
US7632647B2
(en)
|
2001-04-13 |
2009-12-15 |
Biosite Incorporated |
Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
|
CA2414073A1
(en)
|
2001-05-04 |
2002-11-14 |
Gunars E. Valkirs |
Diagnostic markers of acute coronary syndromes and methods of use thereof
|
US20040219509A1
(en)
*
|
2001-08-20 |
2004-11-04 |
Biosite, Inc. |
Diagnostic markers of stroke and cerebral injury and methods of use thereof
|
JP2005522669A
(ja)
*
|
2001-08-20 |
2005-07-28 |
バイオサイト インコーポレイテッド |
卒中および脳損傷の診断マーカーおよびその使用方法
|
WO2004094460A2
(en)
|
2003-04-17 |
2004-11-04 |
Ciphergen Biosystems, Inc. |
Polypeptides related to natriuretic peptides and methods of their identification and use
|
WO2005033327A2
(en)
*
|
2003-09-29 |
2005-04-14 |
Biosite Incorporated |
Methods and compositions for the diagnosis of sepsis
|
ATE449337T1
(de)
|
2003-12-12 |
2009-12-15 |
Inverness Medical Switzerland |
Assay
|
US6991911B2
(en)
*
|
2003-12-15 |
2006-01-31 |
Dade Behring Inc. |
Assay for entactogens
|
US7022492B2
(en)
*
|
2003-12-15 |
2006-04-04 |
Dade Behring Inc. |
Ecstasy haptens and immunogens
|
US20050130243A1
(en)
*
|
2003-12-15 |
2005-06-16 |
Zheng Yi F. |
Assay for entactogens
|
US7037669B2
(en)
*
|
2004-03-22 |
2006-05-02 |
Dade Behring Inc. |
Assays for amphetamine and methamphetamine using stereospecific reagents
|
US7115383B2
(en)
*
|
2004-03-22 |
2006-10-03 |
Dade Behring Inc. |
Assays for amphetamine and methamphetamine
|
US20060105419A1
(en)
*
|
2004-08-16 |
2006-05-18 |
Biosite, Inc. |
Use of a glutathione peroxidase 1 as a marker in cardiovascular conditions
|
JP4581571B2
(ja)
*
|
2004-09-06 |
2010-11-17 |
富士ゼロックス株式会社 |
粒子のマレイミジル基量を測定する定量方法
|
US20060051825A1
(en)
*
|
2004-09-09 |
2006-03-09 |
Buechler Kenneth F |
Methods and compositions for measuring canine BNP and uses thereof
|
US20060084184A1
(en)
*
|
2004-10-19 |
2006-04-20 |
Renovar Incorporated |
Reagents for urine-based immunological assays
|
US20080050832A1
(en)
*
|
2004-12-23 |
2008-02-28 |
Buechler Kenneth F |
Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
|
WO2006078813A2
(en)
*
|
2005-01-21 |
2006-07-27 |
Biosite Incorporated |
Arginine analogs, and methods for their synthesis and use
|
WO2006135781A2
(en)
*
|
2005-06-09 |
2006-12-21 |
Biosite, Inc. |
Methods and compositions for the diagnosis of venous thromboembolic disease
|
WO2007028070A2
(en)
*
|
2005-08-30 |
2007-03-08 |
Biosite, Inc. |
Use of soluble flt-1 and its fragments in cardiovascular conditions
|
EP1928905B1
(de)
|
2005-09-30 |
2015-04-15 |
AbbVie Deutschland GmbH & Co KG |
Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
|
US20070224643A1
(en)
*
|
2006-03-09 |
2007-09-27 |
Mcpherson Paul H |
Methods and compositions for the diagnosis of diseases of the aorta
|
US20080118924A1
(en)
*
|
2006-05-26 |
2008-05-22 |
Buechler Kenneth F |
Use of natriuretic peptides as diagnostic and prognostic indicators in vascular diseases
|
GB0611116D0
(en)
|
2006-06-06 |
2006-07-19 |
Oxford Genome Sciences Uk Ltd |
Proteins
|
ATE528411T1
(de)
|
2006-06-07 |
2011-10-15 |
Otago Innovation Ltd |
Diagnoseverfahren und -marker
|
US20100311186A1
(en)
*
|
2006-07-28 |
2010-12-09 |
Biosite Incorporated |
Devices and methods for performing receptor binding assays using magnetic particles
|
CA2662629C
(en)
|
2006-09-07 |
2019-08-13 |
University Of Otago |
Bnp signal peptide fragments for acute cardiac disorders
|
WO2008060607A2
(en)
*
|
2006-11-14 |
2008-05-22 |
Biosite Incorporated |
Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
|
EP2095106B1
(en)
*
|
2006-11-14 |
2013-03-20 |
Alere San Diego, Inc. |
Methods and compositions for diagnosis and prognosis of renal artery stenosis
|
US8221995B2
(en)
*
|
2007-03-23 |
2012-07-17 |
Seok-Won Lee |
Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
|
US20090004755A1
(en)
*
|
2007-03-23 |
2009-01-01 |
Biosite, Incorporated |
Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
|
US7903970B2
(en)
*
|
2007-03-30 |
2011-03-08 |
Georgia Tech Research Corporation |
Optical network evaluation systems and methods
|
US20090053832A1
(en)
*
|
2007-08-20 |
2009-02-26 |
Link William F |
Simultaneous assay for determining drugs
|
US7947465B2
(en)
*
|
2007-08-20 |
2011-05-24 |
Bio-Rad Laboratories, Inc. |
Simultaneous assay for determining drugs
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
CN101977933A
(zh)
|
2008-03-12 |
2011-02-16 |
奥塔哥创新有限公司 |
生物标记物
|
WO2009113879A1
(en)
|
2008-03-12 |
2009-09-17 |
Christopher Joseph Pemberton |
Biomarkers
|
US11150250B2
(en)
|
2008-08-28 |
2021-10-19 |
Astute Medical, Inc. |
Methods for diagnosing acute kidney injury or renal failure
|
EP2813848A3
(en)
|
2008-08-29 |
2015-03-11 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
US20110207161A1
(en)
|
2008-10-21 |
2011-08-25 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
EP2364444A4
(en)
|
2008-10-21 |
2012-08-08 |
Astute Medical Inc |
METHOD AND COMPOSITIONS FOR THE DIAGNOSIS AND FORECASTING KIDNEY INJURY AND KIDNEY FAILURES
|
AU2009313189B2
(en)
|
2008-11-10 |
2014-10-23 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
BRPI0921921A2
(pt)
|
2008-11-22 |
2019-09-24 |
Astute Medical Inc |
método para avaliar a condição renal em um indivíduo, e, uso de um ou mais marcadores de lesão renal.
|
US20100204055A1
(en)
*
|
2008-12-05 |
2010-08-12 |
Bonner-Ferraby Phoebe W |
Autoantibody detection systems and methods
|
US20120053072A1
(en)
|
2009-02-06 |
2012-03-01 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
US20120052512A1
(en)
|
2009-02-06 |
2012-03-01 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
CA2767616A1
(en)
|
2009-07-09 |
2011-01-13 |
The Scripps Research Institute |
Gene expression profiles associated with chronic allograft nephropathy
|
US8871459B2
(en)
|
2009-08-07 |
2014-10-28 |
Astute Medical, Inc. |
Method for evaluating renal status by determining beta-2-glycoprotein 1
|
NZ598035A
(en)
|
2009-08-07 |
2014-06-27 |
Astute Medical Inc |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
CN102792161B
(zh)
|
2009-08-28 |
2014-11-12 |
阿斯图特医药公司 |
肾损伤和肾衰竭的诊断及预后的方法及组合物
|
US20130045494A1
(en)
|
2009-09-18 |
2013-02-21 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
CA2774223A1
(en)
|
2009-09-21 |
2011-03-24 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
CA2779902A1
(en)
|
2009-11-07 |
2011-05-12 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
CA2779905A1
(en)
|
2009-11-07 |
2011-05-12 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
JP5951498B2
(ja)
*
|
2009-12-08 |
2016-07-13 |
アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー |
網膜神経線維層変性の治療に使用するためのrgmaタンパク質に対するモノクローナル抗体
|
EP2513649B1
(en)
|
2009-12-20 |
2016-04-20 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
EA201290627A1
(ru)
|
2010-02-05 |
2013-05-30 |
Астьют Медикал, Инк. |
Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
|
EP2531621A4
(en)
|
2010-02-05 |
2013-07-31 |
Astute Medical Inc |
METHOD AND COMPOSITIONS FOR DIAGNOSIS AND FORECASTING kidney injury and kidney insufficiency
|
WO2011097539A1
(en)
|
2010-02-05 |
2011-08-11 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
WO2011162820A1
(en)
|
2010-06-23 |
2011-12-29 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
WO2011106746A1
(en)
|
2010-02-26 |
2011-09-01 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
JP5786020B2
(ja)
|
2010-04-16 |
2015-09-30 |
アボットジャパン株式会社 |
関節リウマチを診断する方法および試薬
|
CA2804297A1
(en)
|
2010-06-23 |
2011-12-29 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
EP3339859A1
(en)
|
2010-06-23 |
2018-06-27 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
EP2596010B1
(en)
|
2010-07-19 |
2017-04-12 |
Otago Innovation Limited |
Signal biomarkers
|
US10557856B2
(en)
|
2010-09-24 |
2020-02-11 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Biomarkers of renal injury
|
CA2813011A1
(en)
|
2010-09-24 |
2012-03-29 |
Astute Medical, Inc. |
Methods and compositions for the evaluation of renal injury using hyaluronic acid
|
CA2811438A1
(en)
|
2010-10-07 |
2012-04-12 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
US8795975B2
(en)
|
2010-11-29 |
2014-08-05 |
Alere San Diego, Inc. |
Methods and compositions for diagnosis and risk prediction in heart failure
|
WO2012094658A2
(en)
|
2011-01-08 |
2012-07-12 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
WO2012102963A1
(en)
|
2011-01-26 |
2012-08-02 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Urine biomarkers for prediction of recovery after acute kidney injury : proteomics
|
US20130330752A1
(en)
|
2011-01-29 |
2013-12-12 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
KR101988600B1
(ko)
*
|
2011-06-29 |
2019-06-12 |
가부시키가이샤 엘에스아이 메디엔스 |
비특이 반응 억제제, 비특이 반응 억제 방법 및 키트
|
JP2014529073A
(ja)
|
2011-08-26 |
2014-10-30 |
アスチュート メディカル,インコーポレイテッド |
腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
|
AU2012340748A1
(en)
|
2011-11-22 |
2014-06-26 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
US10935548B2
(en)
|
2011-12-08 |
2021-03-02 |
Astute Medical, Inc. |
Methods for diagnosis and prognosis of renal injury and renal failure using insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2
|
EP3800200A1
(en)
|
2011-12-14 |
2021-04-07 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
EP2791175A2
(en)
|
2011-12-14 |
2014-10-22 |
Abbvie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
PE20142168A1
(es)
|
2012-01-27 |
2015-01-17 |
AbbVie Deutschland GmbH and Co KG |
Composicion y metodo para el diagnostico y el tratamiento de las enfermedades asociadas a la degeneracion de las neuritas
|
IN2014MN01760A
(no)
|
2012-02-27 |
2015-07-03 |
Astute Medical Inc |
|
US20130245038A1
(en)
|
2012-03-13 |
2013-09-19 |
Abbvie Inc. |
Method For Selecting Or Identifying A Subject For V1B Antagonist Therapy
|
ES2661516T3
(es)
|
2012-03-20 |
2018-04-02 |
Otago Innovation Limited |
Biomarcadores
|
ES2794448T3
(es)
|
2012-04-02 |
2020-11-18 |
Astute Medical Inc |
Procedimientos para el diagnóstico y pronóstico de sepsis
|
WO2013163345A1
(en)
|
2012-04-24 |
2013-10-31 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of stroke or other cerebral injury
|
EP3572809A1
(en)
|
2012-07-23 |
2019-11-27 |
Astute Medical, Inc. |
Methods for diagnosis of sepsis
|
WO2014028339A1
(en)
|
2012-08-11 |
2014-02-20 |
Astute Medical, Inc. |
Evaluating renal injury using hyaluronic acid
|
CN105074466B
(zh)
|
2013-01-17 |
2018-01-09 |
阿斯图特医药公司 |
用于肾损伤和肾衰竭的诊断及预后的方法和组合物
|
EP2970319A4
(en)
|
2013-03-14 |
2016-11-09 |
Alere San Diego Inc |
6-ACETYLMORPHINE ANALOGUE AND METHOD FOR THE SYNTHESIS AND USE
|
US9469686B2
(en)
|
2013-03-15 |
2016-10-18 |
Abbott Laboratories |
Anti-GP73 monoclonal antibodies and methods of obtaining the same
|
WO2014197729A1
(en)
|
2013-06-05 |
2014-12-11 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
EP3632467B1
(en)
|
2013-06-07 |
2023-09-27 |
Duke University |
Inhibitors of complement factor h
|
JP2016528236A
(ja)
|
2013-08-07 |
2016-09-15 |
アスチュート メディカル,インコーポレイテッド |
生物学的試料において改善された性能を有するtimp2のためのアッセイ
|
KR102322057B1
(ko)
|
2013-08-23 |
2021-11-05 |
리아타 파마슈티컬즈, 아이엔씨. |
바독솔론 메틸 또는 이의 유사체를 이용한 내피 기능장애의 치료 및 예방 방법
|
WO2015031626A1
(en)
|
2013-08-28 |
2015-03-05 |
Abbvie Inc. |
Soluble cmet assay
|
CN105556308B
(zh)
|
2013-09-20 |
2018-05-29 |
阿斯图特医药公司 |
用于阑尾炎的诊断和预后及腹痛病因的区分的方法和组合物
|
JP2017501211A
(ja)
|
2013-11-06 |
2017-01-12 |
アスチュート メディカル,インコーポレイテッド |
生体試料中で改善された性能を有するigfbp7のためのアッセイ
|
CN110007084B
(zh)
|
2013-12-03 |
2022-11-18 |
阿斯图特医药公司 |
用于肾损伤和肾衰竭的诊断和预后的方法和组合物
|
EP3090067B1
(en)
|
2013-12-30 |
2020-07-22 |
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. |
Genomic rearrangements associated with prostate cancer and methods of using the same
|
EP3825418A3
(en)
|
2014-05-22 |
2021-09-15 |
The Scripps Research Institute |
Molecular signatures for distinguishing liver transplant rejections or injuries
|
EP3825416A3
(en)
|
2014-05-22 |
2021-09-15 |
The Scripps Research Institute |
Gene expression profiles associated with sub-clinical kidney transplant rejection
|
US10443100B2
(en)
|
2014-05-22 |
2019-10-15 |
The Scripps Research Institute |
Gene expression profiles associated with sub-clinical kidney transplant rejection
|
EP3146077A4
(en)
|
2014-05-22 |
2018-05-02 |
The Scripps Research Institute |
Tissue molecular signatures of kidney transplant rejections
|
US11104951B2
(en)
|
2014-05-22 |
2021-08-31 |
The Scripps Research Institute |
Molecular signatures for distinguishing liver transplant rejections or injuries
|
US11333671B2
(en)
|
2014-10-20 |
2022-05-17 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
WO2016100912A1
(en)
|
2014-12-18 |
2016-06-23 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
WO2016164854A1
(en)
|
2015-04-09 |
2016-10-13 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
JP2018521307A
(ja)
|
2015-05-12 |
2018-08-02 |
アスチュート メディカル,インコーポレイテッド |
腎障害および腎不全の診断および予後のための方法および組成物
|
CA2988980A1
(en)
|
2015-06-11 |
2016-12-15 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
WO2016205740A1
(en)
|
2015-06-17 |
2016-12-22 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of appendicitis and differentiation of causes of abdominal pain
|
CN108291330A
(zh)
|
2015-07-10 |
2018-07-17 |
西弗吉尼亚大学 |
卒中和卒中严重性的标志物
|
US11192857B2
(en)
|
2016-05-18 |
2021-12-07 |
Alere San Diego, Inc. |
2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine analogs and methods for their synthesis and use
|
US11243217B2
(en)
|
2016-06-06 |
2022-02-08 |
Astute Medical, Inc. |
Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
|
NL2017267B1
(en)
|
2016-07-29 |
2018-02-01 |
Aduro Biotech Holdings Europe B V |
Anti-pd-1 antibodies
|
BR112019006706A2
(pt)
|
2016-10-03 |
2019-06-25 |
Abbott Lab |
métodos melhorados para avaliar o estado de gfap em amostras de paciente
|
US11633411B2
(en)
|
2016-10-04 |
2023-04-25 |
University Of Maryland, Baltimore |
Methods of treating sepsis using anti-sepsis lipid A (ASLA) based therapeutics
|
NZ753546A
(en)
|
2016-11-08 |
2022-10-28 |
Reata Pharmaceuticals Holdings Llc |
Methods of treating alport syndrome using bardoxolone methyl or analogs thereof
|
AU2018207151B2
(en)
|
2017-01-12 |
2024-02-29 |
Astute Medical, Inc. |
Methods and compositions for evaluation and treatment of renal injury and renal failure based on C-C motif chemokine ligand 14 measurement
|
EP3593134A1
(en)
|
2017-03-09 |
2020-01-15 |
Cleara Biotech B.V. |
Biomarkers for cellular senescence
|
CA3052513A1
(en)
|
2017-03-23 |
2018-09-27 |
Abbott Laboratories |
Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
|
CN110546513A
(zh)
|
2017-04-15 |
2019-12-06 |
雅培实验室 |
使用早期生物标记物帮助超急性诊断和确定人类受试者中的创伤性脑损伤的方法
|
EP3635407A1
(en)
|
2017-04-28 |
2020-04-15 |
Abbott Laboratories |
Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
|
US10865238B1
(en)
|
2017-05-05 |
2020-12-15 |
Duke University |
Complement factor H antibodies
|
WO2018208684A1
(en)
|
2017-05-07 |
2018-11-15 |
Astute Medical, Inc. |
Use of insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2 in the management of renal replacement therapy
|
US10866251B2
(en)
|
2017-05-25 |
2020-12-15 |
Abbott Laboratories |
Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
|
BR112019025387A2
(pt)
|
2017-05-30 |
2020-07-07 |
Abbott Laboratories |
métodos para auxiliar no diagnóstico e avaliação de uma lesão traumática cerebral branda em um indivíduo humano com o uso de troponina cardíaca i e biomarcadores precoces
|
WO2019010131A1
(en)
|
2017-07-03 |
2019-01-10 |
Abbott Laboratories |
IMPROVED METHODS FOR MEASURING CARBOXY TERMINATION HYDROLASE LEVELS OF UBIQUITIN L1 IN BLOOD
|
JP7379165B2
(ja)
|
2017-12-09 |
2023-11-14 |
アボット・ラボラトリーズ |
Gfapとuch-l1との組合せを使用する、ヒト対象における外傷性脳損傷を診断及び査定する一助となるための方法
|
JP7344801B2
(ja)
|
2017-12-09 |
2023-09-14 |
アボット・ラボラトリーズ |
グリア原線維性酸性タンパク質(gfap)及び/又はユビキチンカルボキシ末端ヒドロラーゼl1(uch-l1)を使用する、整形外科損傷を負っており、軽度外傷性脳損傷(tbi)などの頭部への損傷を負ったか又は負った可能性がある対象についての診断及び査定の一助となるための方法
|
CN112041341B
(zh)
|
2017-12-28 |
2024-05-24 |
机敏医药股份有限公司 |
Ccl14的抗体和检测
|
CA3084064A1
(en)
|
2017-12-29 |
2019-07-04 |
Abbott Laboratories |
Novel biomarkers and methods for diagnosing and evaluating traumatic brain injury
|
US20210239700A1
(en)
|
2018-05-04 |
2021-08-05 |
Abbott Laboratories |
Hbv diagnostic, prognostic, and therapeutic methods and products
|
WO2020051231A1
(en)
|
2018-09-04 |
2020-03-12 |
H. Lee Moffitt Cancer Center & Research Institute Inc. |
Use of delta-tocotrienol for treating cancer
|
EP4375669A2
(en)
|
2018-12-28 |
2024-05-29 |
Abbott Laboratories |
Direct detection of single molecules on microparticles
|
WO2020144535A1
(en)
|
2019-01-08 |
2020-07-16 |
Aduro Biotech Holdings, Europe B.V. |
Methods and compositions for treatment of multiple myeloma
|
EP3931573A1
(en)
|
2019-03-01 |
2022-01-05 |
Abbott Laboratories |
Methods for predicting major adverse cardiovascular events in subjects with coronary artery disease
|
CA3175523A1
(en)
|
2020-04-13 |
2021-10-21 |
Antti Virtanen |
Methods, complexes and kits for detecting or determining an amount of a .beta.-coronavirus antibody in a sample
|
US20230255982A1
(en)
|
2020-05-09 |
2023-08-17 |
Reata Pharmaceuticals Holdings, LLC |
Methods of treating covid-19 using bardoxolone methyl or analogs thereof
|
MX2022015287A
(es)
|
2020-06-01 |
2023-02-22 |
Loop Diagnostics S L |
Metodo y kit para la deteccion temprana de septicemia.
|
EP4193151A1
(en)
|
2020-08-04 |
2023-06-14 |
Abbott Rapid Diagnostics International Unlimited Company |
Assays for detecting sars-cov-2
|
EP4193149A1
(en)
|
2020-08-04 |
2023-06-14 |
Abbott Laboratories |
Improved methods and kits for detecting sars-cov-2 protein in a sample
|
WO2022099216A1
(en)
*
|
2020-11-09 |
2022-05-12 |
Children's Medical Center Corporation |
Systems and methods for high throughput screening of molecular interactions
|
WO2022119841A1
(en)
|
2020-12-01 |
2022-06-09 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
WO2023102384A1
(en)
|
2021-11-30 |
2023-06-08 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
AU2021397631A1
(en)
|
2020-12-11 |
2023-07-20 |
Reata Pharmaceuticals Holdings, LLC |
Synthetic triterpenoids for use in therapy
|
EP4271998A1
(en)
|
2020-12-30 |
2023-11-08 |
Abbott Laboratories |
Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
|
WO2022245920A1
(en)
|
2021-05-18 |
2022-11-24 |
Abbott Laboratories |
Methods of evaluating brain injury in a pediatric subject
|
BR112023026199A2
(pt)
|
2021-06-14 |
2024-03-05 |
Abbott Lab |
Métodos para diagnosticar ou auxiliar no diagnóstico de lesão cerebral causada por energia acústica, energia eletromagnética, onda de sobrepressurização e/ou rajada de vento
|
WO2023028186A1
(en)
|
2021-08-27 |
2023-03-02 |
Abbott Laboratories |
Methods for detecting immunoglobulin g, subclass 4 (igg4) in a biological sample
|
WO2023034777A1
(en)
|
2021-08-31 |
2023-03-09 |
Abbott Laboratories |
Methods and systems of diagnosing brain injury
|
CA3232176A1
(en)
|
2021-09-30 |
2023-04-06 |
Beth MCQUISTON |
Methods and systems of diagnosing brain injury
|
CA3240822A1
(en)
|
2021-12-17 |
2023-06-22 |
Tony Lee |
Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
|
WO2023129942A1
(en)
|
2021-12-28 |
2023-07-06 |
Abbott Laboratories |
Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
|
WO2023144206A1
(en)
|
2022-01-27 |
2023-08-03 |
Sanofi Pasteur |
Modified vero cells and methods of using the same for virus production
|
WO2023150652A1
(en)
|
2022-02-04 |
2023-08-10 |
Abbott Laboratories |
Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
|
WO2023212298A1
(en)
|
2022-04-29 |
2023-11-02 |
Broadwing Bio Llc |
Bispecific antibodies and methods of treating ocular disease
|
WO2023212293A1
(en)
|
2022-04-29 |
2023-11-02 |
Broadwing Bio Llc |
Complement factor h related 4-specific antibodies and uses thereof
|
WO2023212294A1
(en)
|
2022-04-29 |
2023-11-02 |
Broadwing Bio Llc |
Angiopoietin-related protein 7-specific antibodies and uses thereof
|
WO2024059692A1
(en)
|
2022-09-15 |
2024-03-21 |
Abbott Laboratories |
Hbv diagnostic, prognostic, and therapeutic methods and products
|
WO2024059708A1
(en)
|
2022-09-15 |
2024-03-21 |
Abbott Laboratories |
Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
|